TN2012000281A1 - Mglu2 agonists - Google Patents
Mglu2 agonistsInfo
- Publication number
- TN2012000281A1 TN2012000281A1 TNP2012000281A TN2012000281A TN2012000281A1 TN 2012000281 A1 TN2012000281 A1 TN 2012000281A1 TN P2012000281 A TNP2012000281 A TN P2012000281A TN 2012000281 A TN2012000281 A TN 2012000281A TN 2012000281 A1 TN2012000281 A1 TN 2012000281A1
- Authority
- TN
- Tunisia
- Prior art keywords
- agonists
- mglu2
- mglu2 agonists
- novel
- schizophrenia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382290 | 2009-12-21 | ||
| PCT/US2010/060371 WO2011084437A1 (en) | 2009-12-21 | 2010-12-15 | Mglu2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2012000281A1 true TN2012000281A1 (en) | 2013-12-12 |
Family
ID=42026702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2012000281A TN2012000281A1 (en) | 2009-12-21 | 2012-06-01 | Mglu2 agonists |
Country Status (35)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2540728T (lt) | 2010-02-17 | 2019-06-25 | Takeda Pharmaceutical Company Limited | Heterociklinis junginys |
| TWI520935B (zh) * | 2010-11-18 | 2016-02-11 | 美國禮來大藥廠 | 作為ｍＧｌｕＲ２／３拮抗劑之４－經取代－３－苯基磺醯基甲基－雙環［３.１.０］己烷化合物 |
| AU2011329136B2 (en) * | 2010-11-18 | 2014-11-06 | Eli Lilly And Company | 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists |
| SI2721012T1 (sl) | 2011-06-17 | 2016-08-31 | Eli Lilly And Company | Derivati biciklo(3.1.0)heksan-2,6-dikarboksilne kisline kot agonisti mglu2 receptorja |
| AR089718A1 (es) * | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
| EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
| CN109999025A (zh) | 2014-01-21 | 2019-07-12 | 詹森药业有限公司 | 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途 |
| LT3277270T (lt) | 2015-04-01 | 2022-01-10 | Akebia Therapeutics, Inc. | Kompozicijos ir būdai skirti anemijos gydymui |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5576323A (en) * | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| US5688826A (en) | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
| GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
| ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| EP1351925A1 (en) * | 2001-01-11 | 2003-10-15 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| HUP0400620A3 (en) * | 2001-01-11 | 2012-09-28 | Lilly Co Eli | Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds |
| WO2002068380A1 (en) * | 2001-02-22 | 2002-09-06 | Eli Lilly And Company | Synthetic excitatory amino acids |
| EA011231B1 (ru) * | 2002-06-11 | 2009-02-27 | Эли Лилли Энд Компани | Пролекарство возбуждающей аминокислоты и его применение |
| JP4984529B2 (ja) * | 2003-06-26 | 2012-07-25 | 大正製薬株式会社 | ２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体 |
| TWI520935B (zh) * | 2010-11-18 | 2016-02-11 | 美國禮來大藥廠 | 作為ｍＧｌｕＲ２／３拮抗劑之４－經取代－３－苯基磺醯基甲基－雙環［３.１.０］己烷化合物 |
| AU2011329136B2 (en) * | 2010-11-18 | 2014-11-06 | Eli Lilly And Company | 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists |
-
2010
- 2010-12-09 AR ARP100104553A patent/AR079343A1/es active IP Right Grant
- 2010-12-09 JO JO2010439A patent/JO2978B1/en active
- 2010-12-10 TW TW099143362A patent/TWI477490B/zh active
- 2010-12-15 KR KR1020127015935A patent/KR101395356B1/ko active Active
- 2010-12-15 ES ES10798419T patent/ES2435651T3/es active Active
- 2010-12-15 EA EA201290558A patent/EA020229B1/ru not_active IP Right Cessation
- 2010-12-15 US US12/968,352 patent/US8318184B2/en active Active
- 2010-12-15 MX MX2012007332A patent/MX2012007332A/es active IP Right Grant
- 2010-12-15 DK DK10798419.7T patent/DK2516406T3/da active
- 2010-12-15 HR HRP20131052AT patent/HRP20131052T1/hr unknown
- 2010-12-15 EP EP10798419.7A patent/EP2516406B1/en active Active
- 2010-12-15 UA UAA201206909A patent/UA107684C2/ru unknown
- 2010-12-15 JP JP2012544727A patent/JP5779190B2/ja active Active
- 2010-12-15 RS RS20130530A patent/RS53063B/sr unknown
- 2010-12-15 CA CA2784667A patent/CA2784667C/en active Active
- 2010-12-15 NZ NZ600305A patent/NZ600305A/en unknown
- 2010-12-15 PH PH1/2012/501253A patent/PH12012501253A1/en unknown
- 2010-12-15 CN CN201080058183.2A patent/CN102695701B/zh active Active
- 2010-12-15 PL PL10798419T patent/PL2516406T3/pl unknown
- 2010-12-15 WO PCT/US2010/060371 patent/WO2011084437A1/en not_active Ceased
- 2010-12-15 MY MYPI2012002794A patent/MY160618A/en unknown
- 2010-12-15 PT PT107984197T patent/PT2516406E/pt unknown
- 2010-12-15 SI SI201030387T patent/SI2516406T1/sl unknown
- 2010-12-15 AU AU2010340039A patent/AU2010340039B2/en active Active
- 2010-12-15 BR BR112012017188-7A patent/BR112012017188B1/pt active IP Right Grant
- 2010-12-15 SG SG2012045563A patent/SG181836A1/en unknown
- 2010-12-15 PE PE2012000856A patent/PE20121688A1/es active IP Right Grant
-
2012
- 2012-05-24 IL IL220011A patent/IL220011A/en active IP Right Grant
- 2012-05-30 HN HN2012001160A patent/HN2012001160A/es unknown
- 2012-06-01 TN TNP2012000281A patent/TN2012000281A1/en unknown
- 2012-06-13 CR CR20120322A patent/CR20120322A/es unknown
- 2012-06-14 MA MA34967A patent/MA33824B1/fr unknown
- 2012-06-19 DO DO2012000173A patent/DOP2012000173A/es unknown
- 2012-06-20 EC ECSP12011989 patent/ECSP12011989A/es unknown
-
2013
- 2013-11-14 CY CY20131101012T patent/CY1114880T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000281A1 (en) | Mglu2 agonists | |
| TN2011000673A1 (en) | Bace inhibitors | |
| PH12012501355A1 (en) | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | |
| EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
| PH12014502697B1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| UA104885C2 (uk) | Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів | |
| MX2012008141A (es) | Compuestos y metodos. | |
| CR10955A (es) | Nuevo procedimiento de sintesis de la agomelatina | |
| PH12013500500A1 (en) | Fused heteroaryls and their uses | |
| MY161473A (en) | Compositions, synthesis, and methods of utilizing arylpiperazine derivatives | |
| CR20120362A (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo | |
| CR10960A (es) | Nuevo procedimiento de sintesis de la agomelatina | |
| MX2012005155A (es) | Compuestos de quinazolina. | |
| CR10934A (es) | Nuevo procedimiento de sintesis de la agomelatina | |
| UA38601U (en) | 2,2'-dithioxo-4,4'-dioxo-[5,5']-bithiazolidinyl-idene-diyl-3,3'-dibutanoic acid diarylamides having antitumor activity | |
| CY1117682T1 (el) | Παραγωγα δικυκλο(3.1.0)εξανο-2,6-δικαρβοξυλικου οξεος ως αγωνιστης του υποδοχεα mglu2 | |
| UA79655U (en) | Compounds n-para-methoxyphenyl-3-(7'-theophylline-8'-bromo)-succinimide and n-ortho-methoxyphenyl-3-(7'-theophylline-8with potential physiological properties | |
| UA35938U (en) | 1-phenyl-o-tolylamino-1,5-dihydropyrrol-2-one having antioxidant activity | |
| UA42812U (ru) | Использование мази тиотриазолина в качестве агента, обладающего фотопротекторными свойствами | |
| TN2010000583A1 (en) | Organic compounds | |
| UA35660U (en) | Use of antihomotoxic preparations as cytoprotectors | |
| UA41660U (en) | Use of jacton and mexidol as actoprotector | |
| UA41922U (ru) | Применение альтана как вещества с противолучевыми свойствами | |
| UA64452U (ru) | Применение гена аполипопротеида Е (апоЕ) в качестве средства для профилактики кардиосклероза | |
| UA87255C2 (en) | Use of n-(2-(morpholine-4-yl)propyl)-2-naphthalimidoacetamide as interferone-inducing antiviral agent |